All In Biotech

Free tool

FAERS Monitor: Ampyra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022250 or its brand name (Ampyra, Dalfampridine). Reports on generic versions are filed under their own applications.

Reports

71,576

Serious

20,310

28% of reports

Hospitalization

10,210

Death reported

1,771

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • gait disturbance10,994
  • drug ineffective8,325
  • fall7,361
  • fatigue5,556
  • balance disorder4,909
  • multiple sclerosis relapse4,788
  • therapy cessation4,511
  • dizziness4,000
  • urinary tract infection3,747
  • condition aggravated3,514
  • asthenia3,471
  • insomnia3,311
  • headache3,274
  • multiple sclerosis3,136
  • mobility decreased3,008

Reports by year received

View as table
YearReports
20061
20082
20096
2010686
2011837
20121,050
20131,618
20146,349
20157,532
201612,012
201710,164
201810,789
20197,166
20203,152
20212,695
20222,758
20232,247
2024992
2025748
2026772

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,982,583 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
therapy cessationSignal4,51128.227.4108,249
multiple sclerosis relapseSignal4,78822.021.489,524
multiple sclerosisSignal3,13620.619.854,620
gait disturbanceSignal10,99417.817.5166,286
balance disorderSignal4,90917.617.172,931
mobility decreasedSignal3,00812.812.331,440
fallSignal7,3616.66.534,915
urinary tract infectionSignal3,7476.66.417,469
insomniaSignal3,3113.73.66,481
condition aggravatedSignal3,5143.43.36,047
astheniaSignal3,4712.72.63,833
dizzinessSignal4,0002.42.33,209
fatigueSignal5,5562.12.13,321
drug ineffective8,3251.91.83,519
headache3,2741.51.5630

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.